Fractionated Carboplatin Radiosensitization
| Autor: | Emmanuel S. Helidonis, Irene Stefanaki, Eugenios Koumandakis, Alexandra Giatromanolaki, Angelos Kranidis, V. Georgoulias, Athena Armenaki, Michael I. Koukourakis, Chryssi Frangiadaki |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male Radiation-Sensitizing Agents Cancer Research medicine.medical_specialty Lung Neoplasms Nausea medicine.medical_treatment Urology Antineoplastic Agents Radiation-Protective Agents Neutropenia Carboplatin chemistry.chemical_compound Amifostine Granulocyte Colony-Stimulating Factor medicine Humans Erythropoietin Aged Pelvic Neoplasms Chemotherapy business.industry Middle Aged medicine.disease Combined Modality Therapy Recombinant Proteins Granulocyte colony-stimulating factor Radiation therapy Oncology chemistry Anesthesia Toxicity Female medicine.symptom business medicine.drug |
| Zdroj: | American Journal of Clinical Oncology. 21:595-601 |
| ISSN: | 0277-3732 |
| DOI: | 10.1097/00000421-199812000-00013 |
| Popis: | Carboplatin is one of the most common drugs used for radiochemotherapy of cancer. However, the best way to combine the drug with fractionated radiotherapy has not been established. In the present study the authors investigated which maximum tolerated daily bolus dose of carboplatin would allow safe radiopotentiation for 10 consecutive radiotherapy days, the scheme being repeated twice during the 6 weeks that a conventional radiotherapy scheme lasts. Seventy-two patients with lung or pelvis malignancies were included in a dose escalation study. Twenty-four patients comprised the first baseline cohort and were treated with radiotherapy alone. The daily dose of carboplatin was escalated starting from 38 mg/m 2 daily (for 10 days) and increasing by 7 mg/ m 2 per day. Six patients were to be included in each cohort. All 12 patients treated at the 38 mg/m 2 and 45 mg/m 2 dose level completed two cycles of 10-day carboplatin treatment with no grade III-IV toxicity. Granulocyte colony-stimulating factor effectively averted the incidence of neutropenia and allowed the administration of the second carboplatin 10-day cycle in five of six patients at the 52 mg/m 2 daily dose level. Platelet grade III-IV toxicity was observed in all 12 patients (six supported with granulocyte colony-stimulating factor and six with granulocyte colony-stimulating factor and recombinant human erythropoietin) treated at the 59 mg/m 2 daily dose level and none of them received the second cycle of chemotherapy. Twelve patients were treated at the same dose level using amifostine 500 mg before carboplatin infusion. Two patients interrupted chemotherapy because of severe nausea and vomiting. Nine of 10 who accomplished the 10-day treatment had platelet levels more than 90,000/μl on day 28 and completed the second 10-day cycle without severe toxicity. Acute radiation toxicity did not increase in the carboplatin cohorts. In this study the authors established a high-dose fractionated carboplatin schedule that can be safely administered during radical radiotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|